Market Watch
09 Jul 2026, 09:53 UTC · 2h ago
Major drugmaker loses $27 billion in market value after failed trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Market Watch
09 Jul 2026, 09:53 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
A heart disease drug developed by two companies failed its Phase III trial. — Phase III failures typically lead to significant stock price drops as they represent the final hurdle before commercialization and regulatory approval.
-0.90Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Continue reading
6 related stories
Top 2 movers · tap to explore
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Invezz
3h ago
